Revealing Uncharted Biology with Single Cell Multiplex Proteomic Technologies Platforms

Wendy J. Fantl, PhD, is currently Head of Systems-level Translational Discovery Research in the Department of Discovery Sciences in Biomedical Research at Novartis. Wendy earned her Ph.D. in protein biochemistry from Rockefeller University and completed her postdoctoral studies at University of California, San Francisco focusing on receptor tyrosine kinase signal transduction. She spent over a decade at Chiron Corporation, where she applied her signaling expertise to targeting kinases. Subsequently, as Vice President of Cancer Biology at Nodality, she developed diagnostic phospho-flow tests for leukemias. In 2010, Wendy returned to academia and joined Stanford University, where her lab applied single cell multiplex proteomic technologies focusing on human high-grade serous ovarian cancer and clear cell renal carcinoma focusing on the tumor immune microenvironment and the DNA damage response. Wendy joined Novartis in 2022 to lead a team dedicated to using these technologies to further the mechanistic understanding of drug responses in patients, aligning with her commitment to patient care.